Perkins Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Perkins Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-218	Closed	-$25K	–	112
2016 Q3	$25K	Sell	218 -96	-31%	-$10.7K	0.03%	108
2016 Q2	$30K	Sell	314 -68	-18%	-$8.34K	0.03%	110
2016 Q1	$44K	Sell	382 -76	-17%	-$9.71K	0.06%	107
2015 Q4	$77K	Sell	458 -254	-36%	-$48.9K	0.08%	111
2015 Q3	$148K	Sell	712 -192	-21%	-$67.4K	0.16%	103
2015 Q2	$446K	Sell	904 -25	-3%	-$10.1K	0.39%	77
2015 Q1	$449K	Buy	929 +708	+320%	+$409K	0.38%	85
2014 Q4	$126K	Sell	221 -60	-21%	-$43.2K	0.11%	118
2014 Q3	$285K	Buy	+281	New	+$332K	0.24%	100

Other funds holding VRDN

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perkins Capital Management's VRDN Position: Q4 2016 in Review

Perkins Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2016, closing a stake of 218 shares — an estimated $25K sold.

Perkins Capital Management first reported a position in VRDN in Q3 2014 and held it in 9 quarters. The position peaked at $449K in Q1 2015. 8 funds tracked by Wall St. Rank hold VRDN as of Q4 2016.

Perkins Capital Management reported no remaining Viridian Therapeutics position as of Q4 2016 after selling out during the quarter.
Perkins Capital Management sold 218 Viridian Therapeutics shares in Q4 2016, an estimated $25K.
Perkins Capital Management first reported a position in Viridian Therapeutics in Q3 2014 and held it in 9 quarters.
Perkins Capital Management's Viridian Therapeutics position peaked at $449K in Q1 2015.
8 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2016.

Based on Perkins Capital Management's 13F filing for Q4 2016, filed 1 Feb 2017.